Phase 3 Data Available on Pevonedistat for AML, MDS, CMML
PhotoLizM / Pixabay

Phase 3 Data Available on Pevonedistat for AML, MDS, CMML

In the Phase 3 PANTHER clinical trial, also known as the Pevonedistat-3001 study, researchers were evaluating pevonedistat in conjunction with azacitidine for patients with acute myeloid leukemia (AML), myelodysplastic syndromes…

Continue Reading Phase 3 Data Available on Pevonedistat for AML, MDS, CMML
September 7 is World Duchenne Awareness Day: Spreading Duchenne Muscular Dystrophy Awareness
source: pixabay.com

September 7 is World Duchenne Awareness Day: Spreading Duchenne Muscular Dystrophy Awareness

September 7, 2021 will be recognized as World Duchenne Awareness Day. This day will be set aside in recognition of awareness surrounding Duchenne muscular dystrophy, a rare and debilitating genetic…

Continue Reading September 7 is World Duchenne Awareness Day: Spreading Duchenne Muscular Dystrophy Awareness
AI Vastly Improves Enrollment in Rare Disease Clinical Trials
https://pixabay.com/en/technology-robot-human-hand-2025795/

AI Vastly Improves Enrollment in Rare Disease Clinical Trials

Clinical trial recruitment has always been challenging. It is especially challenging for therapies being tested for rare diseases, an already small population. Clinical trials for rare diseases are small out…

Continue Reading AI Vastly Improves Enrollment in Rare Disease Clinical Trials
DRC Confirms 2 Yellow Fever Cases
Source: Pixabay.com

DRC Confirms 2 Yellow Fever Cases

On July 18, 2021, the World Health Organization (WHO) first reported two cases of yellow fever within the Democratic Republic of the Congo (DRC), shares Outbreak News Today. This rare…

Continue Reading DRC Confirms 2 Yellow Fever Cases

European Study Demonstrates Need for Faster Diagnosis and Improved Counseling for Pulmonary Fibrosis Patients

A recent study has uncovered just how many people with pulmonary fibrosis (PF) do not receive an immediate diagnosis. This study conducted in Europe was published in Frontiers of Medicine.…

Continue Reading European Study Demonstrates Need for Faster Diagnosis and Improved Counseling for Pulmonary Fibrosis Patients
Abecma for MM Approved by European Commission
source: pixabay.com

Abecma for MM Approved by European Commission

According to Pharmaceutical Business Review, Abecma (idecabtagene vicleucel), a CAR T-cell therapy designed to treat patients with relapsed and refractory (R/R) multiple myeloma (MM), received conditional marketing authorization from the…

Continue Reading Abecma for MM Approved by European Commission